{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:42:07Z","timestamp":1791945727370,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T00:00:00Z","timestamp":1727827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.canep.2024.102678","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T19:57:21Z","timestamp":1727812641000},"page":"102678","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Mapping the patient journey and treatment patterns in early-stage (stage I-III) non-small cell lung cancer"],"prefix":"10.1016","volume":"93","author":[{"given":"Sarah","family":"Sharman Moser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Yaari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lior","family":"Apter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3495-3930","authenticated-orcid":false,"given":"Bernadette","family":"Poellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Rheenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4879-4770","authenticated-orcid":false,"given":"Ashwini","family":"Arunachalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3107-5828","authenticated-orcid":false,"given":"Moshe","family":"Hoshen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivan","family":"Gazit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nava","family":"Siegelmann-Danieli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2024.102678_bib1","series-title":"World cancer report 2014","author":"Wild","year":"2014"},{"issue":"10","key":"10.1016\/j.canep.2024.102678_bib2","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1016\/j.jtho.2016.05.021","article-title":"The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics","volume":"11","author":"Cheng","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canep.2024.102678_bib3","unstructured":"WHO. Lung Cancer 2023 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/lung-cancer#:\u223c:text=Lung%20cancer%20is%20the%20leading,approximately%2085%25%20of%20all%20cases."},{"issue":"6","key":"10.1016\/j.canep.2024.102678_bib4","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1183\/09031936.04.00113603","article-title":"Lung cancer: clinical presentation and specialist referral time","volume":"24","author":"Buccheri","year":"2004","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.canep.2024.102678_bib5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/thx.2004.029264","article-title":"Is late diagnosis of lung cancer inevitable? Interview study of patients\u2019 recollections of symptoms before diagnosis","volume":"60","author":"Corner","year":"2005","journal-title":"Thorax"},{"key":"10.1016\/j.canep.2024.102678_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.canep.2019.04.014","article-title":"Lung cancer patients' journey from first symptom to treatment: results from a Greek registry","volume":"60","author":"Kourlaba","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.canep.2024.102678_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2022.102156","article-title":"Predictors of treatment initiation and mapping the cancer diagnostic pathway: a retrospective observational cohort study of patients with metastatic non-small cell lung cancer","volume":"79","author":"Sharman Moser","year":"2022","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.canep.2024.102678_bib8","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ejca.2017.10.003","article-title":"Time to diagnosis and treatment for cancer patients in the Netherlands: room for improvement?","volume":"87","author":"Helsper","year":"2017","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.canep.2024.102678_bib9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.canep.2024.102678_bib10","doi-asserted-by":"crossref","unstructured":"Ettinger D.S., Wood D.E., Aisner D.L., Akerley W., Bauman J.R., Bharat A., et al. NCCN Guidelines Insights: Non\u2013Small Cell Lung Cancer, Version 5.2021. 2021.","DOI":"10.6004\/jnccn.2021.0013"},{"issue":"3","key":"10.1016\/j.canep.2024.102678_bib11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3857\/roj.2023.00430","article-title":"Exploring the past, present, and future of postoperative radiotherapy for N2 stage non-small cell lung cancer","volume":"41","author":"Kim","year":"2023","journal-title":"Radiat. Oncol. J."},{"issue":"1","key":"10.1016\/j.canep.2024.102678_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5306\/wjco.v8.i1.1","article-title":"Therapeutic management options for stage III non-small cell lung cancer","volume":"8","author":"Yoon","year":"2017","journal-title":"World J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.canep.2024.102678_bib13","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2024.102678_bib14","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.2147\/OTT.S145036","article-title":"Improvement of survival for non-small cell lung cancer over time","author":"Xia","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"10308","key":"10.1016\/j.canep.2024.102678_bib15","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2024.102678_bib16","doi-asserted-by":"crossref","unstructured":"Oselin K., Shim B.Y., Okada M., Bryl M., Bonanno L., Demirag G., et al. Pembrolizumab vs placebo for early-stage non3small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS\/KEYNOTE-091 study. American Society of Clinical Oncology; 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.8520"},{"issue":"21","key":"10.1016\/j.canep.2024.102678_bib17","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2024.102678_bib18","unstructured":"NCCN. Non-Small Cell Lung Cancer Guidelines Version 5.2023 2023 [Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450."},{"issue":"1","key":"10.1016\/j.canep.2024.102678_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40545-023-00529-0","article-title":"The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer","volume":"16","author":"Sharman Moser","year":"2023","journal-title":"J. Pharm. Policy Pract."},{"key":"10.1016\/j.canep.2024.102678_bib20","unstructured":"Cohen R. Membership in Sick Funds 2017 [Available from: \u3008https:\/\/www.btl.gov.il\/Publications\/survey\/Documents\/seker_303.pdf\u3009."},{"issue":"3","key":"10.1016\/j.canep.2024.102678_bib21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ijcard.2010.08.002","article-title":"The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization","volume":"152","author":"Shalev","year":"2011","journal-title":"Int. J. Cardiol."},{"issue":"12","key":"10.1016\/j.canep.2024.102678_bib22","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1023\/B:EJEP.0000006635.36802.c8","article-title":"The epidemiology of diabetes in a large Israeli HMO","volume":"18","author":"Chodick","year":"2003","journal-title":"Eur. J. Epidemiol."},{"key":"10.1016\/j.canep.2024.102678_bib23","first-page":"1","article-title":"Osteoporosis in the community: findings from a novel computerized registry in a Large Health Organization in Israel","volume":"4","author":"Goldshtein","year":"2015","journal-title":"J. Aging Res. Clin. Pract."},{"issue":"6","key":"10.1016\/j.canep.2024.102678_bib24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.canep.2024.102678_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00432-019-03079-8","article-title":"The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients","volume":"146","author":"Wang","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.canep.2024.102678_bib26","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.21037\/jtd-20-3075","article-title":"Prognostic value of symptoms at lung cancer diagnosis: a three-year observational study","volume":"13","author":"Polanco","year":"2021","journal-title":"J. Thorac. Dis."},{"issue":"6","key":"10.1016\/j.canep.2024.102678_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001021","article-title":"Lung cancer symptoms at diagnosis: results of a nationwide registry study","volume":"5","author":"Ruano-Ravina","year":"2020","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.canep.2024.102678_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001977","article-title":"Eliciting symptoms interpreted as normal by patients with early-stage lung cancer: could GP elicitation of normalised symptoms reduce delay in diagnosis? Cross-sectional interview study","volume":"2","author":"Brindle","year":"2012","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.canep.2024.102678_bib29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/bjc.2013.1","article-title":"Measures of promptness of cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18 common and rarer cancers","volume":"108","author":"Lyratzopoulos","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.canep.2024.102678_bib30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/thoraxjnl-2021-216865","article-title":"Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review","volume":"77","author":"Hall","year":"2022","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.canep.2024.102678_bib31","doi-asserted-by":"crossref","first-page":"e2030072-e","DOI":"10.1001\/jamanetworkopen.2020.30072","article-title":"Assessment of time-to-treatment initiation and survival in a cohort of patients with common cancers","volume":"3","author":"Cone","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"9","key":"10.1016\/j.canep.2024.102678_bib32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/thx.2008.109330","article-title":"Timeliness of care in patients with lung cancer: a systematic review","volume":"64","author":"Olsson","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.canep.2024.102678_bib33","unstructured":"Health IMo. Disease Control in the Ministry of Health on Lung Cancer Morbidity in Israel for the Years 1996-2019 2023 [Available from: https:\/\/www.gov.il\/en\/departments\/news\/25122022-01."},{"key":"10.1016\/j.canep.2024.102678_bib34","unstructured":"Health IMo. Report of the National Center for Disease Control in the Ministry of Health on Lung Cancer Morbidity in Israel for the Years 1996-2019 [Available from: https:\/\/www.gov.il\/en\/departments\/news\/25122022-01."},{"key":"10.1016\/j.canep.2024.102678_bib35","unstructured":"\"The difference between life and death\": The pilot for the early detection of lung cancer is a success (hebrew). Israel Today 2023."},{"key":"10.1016\/j.canep.2024.102678_bib36","unstructured":"NCCN. Non-Small Cell Lung Cancer Guidelines Version 2.2024 2024 [Available from: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782124001577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782124001577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T11:30:56Z","timestamp":1732620656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782124001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":36,"alternative-id":["S1877782124001577"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2024.102678","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping the patient journey and treatment patterns in early-stage (stage I-III) non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2024.102678","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. And The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102678"}}